tacrine has been researched along with Cognition Disorders in 39 studies
Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.
tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
Excerpt | Relevance | Reference |
---|---|---|
" This article reviews basic approaches in pharmacoeconomics; current knowledge of costs related to dementia; assessment of quality of life in patients with cognitive impairment; models of relationships among degree of cognitive impairment, caregiver burden, and health care utilization; existing pharmacoeconomic guidelines for drug studies; pharmacoeconomic studies of tacrine, a drug used in Alzheimer disease; and further work needed to advance the critical area of pharmacoeconomic studies in dementia." | 3.69 | Pharmacoeconomics of dementia. ( Whitehouse, PJ, 1997) |
"Factor analysis methodology applied to Alzheimer's Disease Assessment Scale (ADAS) subtest profiles for patients in two large-scale clinical trials of the antidementia drug tacrine yielded three oblique factors interpreted as dysfunctions in memory, language, and praxis." | 2.68 | Cardinal features of cognitive dysfunction in Alzheimer's disease: a factor-analytic study of the Alzheimer's Disease Assessment Scale. ( Gracon, SI; Overall, JE; Srirama, MK; Talwalker, S, 1996) |
"Men and women with probable Alzheimer's disease, at least 50 years old, mildly to moderately impaired, without other significant medical conditions." | 2.67 | A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. ( Dolan-Ureno, J; Farlow, M; Gracon, SI; Hershey, LA; Lewis, KW; Sadowsky, CH, 1992) |
"The rapid growth of the world's Alzheimer's disease (AD) population has resulted in a tremendous financial burden on society, a situation exacerbated by the fact that the funding of health and social services faces increasing restrictions in the coming years." | 2.40 | An economic perspective on Alzheimer's disease. ( Trabucchi, M, 1999) |
"Developing treatment guidelines for Alzheimer's disease and other dementias depends primarily on a literature review." | 2.39 | Developing treatment guidelines for Alzheimer's disease and other dementias. ( Rabins, PV, 1996) |
" Chronic administration of B3C for 21 days prevented the memory impairments of the AD model mice in a dose-dependent manner." | 1.43 | Bis(propyl)-cognitin Prevents β-amyloid-induced Memory Deficits as Well as Synaptic Formation and Plasticity Impairments via the Activation of PI3-K Pathway. ( An, P; Chen, X; Feng, C; Han, Y; Huang, M; Jiang, L; Wang, Q; Wang, Y; Wei, X; Xu, S, 2016) |
"Tacrine was given in doses between 80 and to 160 mg daily for 13-31 months." | 1.30 | Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities. ( Amberla, K; Andersson, J; Hartvig, P; Hellström-Lindahl, E; Johansson, M; Långström, B; Lilja, A; Lundqvist, H; Nordberg, A; Shigeta, M; Viitanen, M; Winblad, B, 1998) |
"Treatments in Alzheimer's disease include treatment of cognitive impairment and behavioral manifestations (agitation, depression, anxiety, delusions)." | 1.30 | [Drug therapy strategies in Alzheimer's disease]. ( Lacomblez, L, 1998) |
"According to the cholinergic theory of Alzheimer's disease, the cognitive failure depends on a deficit in acetylcholine." | 1.29 | [Use of cholinesterase inhibitors in Alzheimer disease]. ( Sampalmieri, M; Servi, M; Troiani, MP, 1993) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (2.56) | 18.7374 |
1990's | 19 (48.72) | 18.2507 |
2000's | 11 (28.21) | 29.6817 |
2010's | 8 (20.51) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fang, L | 3 |
Appenroth, D | 3 |
Decker, M | 3 |
Kiehntopf, M | 1 |
Lupp, A | 1 |
Peng, S | 1 |
Fleck, C | 3 |
Zhang, Y | 2 |
Lehmann, J | 2 |
Jumpertz, S | 1 |
Mohr, K | 1 |
Tränkle, C | 1 |
Jiang, L | 1 |
Huang, M | 1 |
Xu, S | 1 |
Wang, Y | 1 |
An, P | 1 |
Feng, C | 1 |
Chen, X | 1 |
Wei, X | 1 |
Han, Y | 2 |
Wang, Q | 1 |
Zhang, Z | 1 |
Chen, R | 1 |
An, W | 1 |
Wang, C | 1 |
Liao, G | 1 |
Dong, X | 1 |
Bi, A | 1 |
Yin, Z | 1 |
Luo, L | 1 |
Misik, J | 1 |
Korabecny, J | 1 |
Nepovimova, E | 1 |
Kracmarova, A | 1 |
Kassa, J | 1 |
Liu, JM | 1 |
Wu, PF | 1 |
Rao, J | 1 |
Zhou, J | 1 |
Shen, ZC | 1 |
Luo, H | 1 |
Huang, JG | 1 |
Liang, X | 1 |
Long, LH | 1 |
Xie, QG | 1 |
Jiang, FC | 1 |
Wang, F | 1 |
Chen, JG | 1 |
Schott, Y | 1 |
Kim, DH | 2 |
Park, SJ | 1 |
Kim, JM | 1 |
Jeon, SJ | 1 |
Cho, YW | 1 |
Son, KH | 1 |
Lee, HJ | 1 |
Moon, JH | 1 |
Cheong, JH | 1 |
Ko, KH | 1 |
Ryu, JH | 1 |
Zhao, Q | 2 |
Matsumoto, K | 2 |
Tsuneyama, K | 1 |
Tanaka, K | 1 |
Li, F | 1 |
Shibahara, N | 1 |
Miyata, T | 1 |
Yokozawa, T | 1 |
Mishima, K | 1 |
Egashira, N | 1 |
Matsumoto, Y | 1 |
Iwasaki, K | 1 |
Fujiwara, M | 1 |
Werber, EA | 1 |
Gandelman-Marton, R | 1 |
Klein, C | 1 |
Rabey, JM | 1 |
Darreh-Shori, T | 1 |
Hellström-Lindahl, E | 2 |
Flores-Flores, C | 1 |
Guan, ZZ | 1 |
Soreq, H | 1 |
Nordberg, A | 2 |
Rispoli, V | 1 |
Rotiroti, D | 1 |
Carelli, V | 1 |
Liberatore, F | 1 |
Scipione, L | 1 |
Marra, R | 1 |
Giorgioni, G | 1 |
Di Stefano, A | 1 |
Sabolek, HR | 1 |
Bunce, JG | 1 |
Chrobak, JJ | 1 |
Simard, M | 1 |
van Reekum, R | 1 |
Xu, Z | 1 |
Zheng, H | 1 |
Law, SL | 1 |
Dong So, D | 1 |
Xue, H | 1 |
Muñoz-Torrero, D | 1 |
Camps, P | 1 |
Lyketsos, CG | 1 |
Colenda, CC | 1 |
Beck, C | 1 |
Blank, K | 1 |
Doraiswamy, MP | 1 |
Kalunian, DA | 1 |
Yaffe, K | 1 |
Murakami, Y | 1 |
Tohda, M | 1 |
Obi, R | 1 |
Shimada, Y | 1 |
Davis, KL | 1 |
Powchik, P | 1 |
Siegfried, KR | 1 |
Sampalmieri, M | 1 |
Troiani, MP | 1 |
Servi, M | 1 |
Talwalker, S | 2 |
Overall, JE | 1 |
Srirama, MK | 1 |
Gracon, SI | 2 |
Kumar, V | 1 |
Goldstein, MZ | 1 |
Doraiswamy, PM | 1 |
Sternon, J | 1 |
Zemlan, FP | 1 |
Schneider, LS | 2 |
Rabins, PV | 1 |
Whitehouse, PJ | 1 |
Peskind, ER | 1 |
Amberla, K | 1 |
Shigeta, M | 1 |
Lundqvist, H | 1 |
Viitanen, M | 1 |
Johansson, M | 1 |
Andersson, J | 1 |
Hartvig, P | 1 |
Lilja, A | 1 |
Långström, B | 1 |
Winblad, B | 1 |
Lacomblez, L | 1 |
Trabucchi, M | 1 |
Farlow, M | 1 |
Hershey, LA | 1 |
Lewis, KW | 1 |
Sadowsky, CH | 1 |
Dolan-Ureno, J | 1 |
Hannington-Kiff, JG | 1 |
10 reviews available for tacrine and Cognition Disorders
Article | Year |
---|---|
The acetylcholinesterase inhibitors for treatment of cognitive and behavioral symptoms in dementia with Lewy bodies.
Topics: Aged; Basal Ganglia Diseases; Behavior; Cholinesterase Inhibitors; Clinical Trials as Topic; Cogniti | 2004 |
Dimeric and hybrid anti-Alzheimer drug candidates.
Topics: Alzheimer Disease; Aminoquinolines; Animals; Binding Sites; Cholinesterase Inhibitors; Cognition Dis | 2006 |
Tacrine.
Topics: Alzheimer Disease; Brain; Clinical Trials as Topic; Cognition Disorders; Double-Blind Method; Drug I | 1995 |
Pharmacodynamic and early clinical studies with velnacrine.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Female; Huma | 1993 |
Advances in pharmacotherapy for decline of memory and cognition in patients with Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Cognition Disorders; Humans; Memory Disorders | 1996 |
New therapeutic approaches to Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Carbamates; Cholinergic Agents; Cholinesterase Inhibitors; Cognitio | 1996 |
Developing treatment guidelines for Alzheimer's disease and other dementias.
Topics: Alzheimer Disease; Antipsychotic Agents; Behavior Therapy; Cognition Disorders; Dementia; Humans; Me | 1996 |
Pharmacologic approaches to cognitive deficits in Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Diso | 1998 |
New therapeutic approaches to cognitive impairment.
Topics: Aged; Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; D | 1998 |
An economic perspective on Alzheimer's disease.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Combi | 1999 |
6 trials available for tacrine and Cognition Disorders
Article | Year |
---|---|
The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients.
Topics: Acetylcholine; Aged; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Cognition Disorders; De | 2003 |
Pharmacodynamic and early clinical studies with velnacrine.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Female; Huma | 1993 |
Cardinal features of cognitive dysfunction in Alzheimer's disease: a factor-analytic study of the Alzheimer's Disease Assessment Scale.
Topics: Aged; Alzheimer Disease; Cognition Disorders; Dose-Response Relationship, Drug; Drug Administration | 1996 |
The cardinal features of cognitive and noncognitive dysfunction and the differential efficacy of tacrine in Alzheimer's disease patients.
Topics: Aged; Alzheimer Disease; Cognition; Cognition Disorders; Double-Blind Method; Female; Humans; Male; | 1996 |
Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; D | 1996 |
A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.
Topics: Alzheimer Disease; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Mental Status Sch | 1992 |
24 other studies available for tacrine and Cognition Disorders
Article | Year |
---|---|
NO-donating tacrine hybrid compounds improve scopolamine-induced cognition impairment and show less hepatotoxicity.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Chemistry, Pharmaceutical; Cognition; Cognition Di | 2008 |
Hybrid molecules from xanomeline and tacrine: enhanced tacrine actions on cholinesterases and muscarinic M1 receptors.
Topics: Acetylcholinesterase; Animals; Butyrylcholinesterase; Central Nervous System Agents; Cholinesterase | 2010 |
Bis(propyl)-cognitin Prevents β-amyloid-induced Memory Deficits as Well as Synaptic Formation and Plasticity Impairments via the Activation of PI3-K Pathway.
Topics: Amyloid beta-Peptides; Animals; Cognition Disorders; Dendrites; Hippocampus; Long-Term Potentiation; | 2016 |
A novel acetylcholinesterase inhibitor and calcium channel blocker SCR-1693 improves Aβ25-35-impaired mouse cognitive function.
Topics: Amyloid beta-Peptides; Animals; Calcium Channel Blockers; Cell Line, Tumor; CHO Cells; Cholinesteras | 2016 |
Effects of novel tacrine-related cholinesterase inhibitors in the reversal of 3-quinuclidinyl benzilate-induced cognitive deficit in rats--Is there a potential for Alzheimer's disease treatment?
Topics: Alzheimer Disease; Animals; Avoidance Learning; Cholinesterase Inhibitors; Cognition Disorders; Done | 2016 |
ST09, a Novel Thioester Derivative of Tacrine, Alleviates Cognitive Deficits and Enhances Glucose Metabolism in Vascular Dementia Rats.
Topics: Acetylcholinesterase; Animals; Apoptosis; Cell Line, Transformed; Cerebral Cortex; Cognition Disorde | 2016 |
Investigation into the in vivo effects of five novel tacrine/ferulic acid and beta-carboline derivatives on scopolamine-induced cognitive impairment in rats using radial maze paradigm.
Topics: Animals; Carbolines; Cognition; Cognition Disorders; Coumaric Acids; Female; Maze Learning; Rats; Ra | 2010 |
Cognitive dysfunctions induced by a cholinergic blockade and Aβ 25-35 peptide are attenuated by salvianolic acid B.
Topics: Amyloid beta-Peptides; Animals; Animals, Newborn; Benzofurans; Cholinergic Antagonists; Cholinestera | 2011 |
Diabetes-induced central cholinergic neuronal loss and cognitive deficit are attenuated by tacrine and a Chinese herbal prescription, kangen-karyu: elucidation in type 2 diabetes db/db mice.
Topics: Animals; Brain; Cholinergic Neurons; Cognition Disorders; Diabetes Mellitus, Experimental; Diabetes | 2011 |
Involvement of reduced acetylcholine release in Delta9-tetrahydrocannabinol-induced impairment of spatial memory in the 8-arm radial maze.
Topics: Acetylcholine; Animals; Cerebral Cortex; Cholinesterase Inhibitors; Cognition Disorders; Dronabinol; | 2002 |
Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients.
Topics: Acetylcholinesterase; Aged; Alternative Splicing; Alzheimer Disease; Blotting, Western; Carbamates; | 2004 |
Choline pivaloyl esters improve in rats cognitive and memory performances impaired by scopolamine treatment or lesions of the nucleus basalis of Meynert.
Topics: Acetylcholinesterase; Analysis of Variance; Animals; Basal Nucleus of Meynert; Cell Count; Choline; | 2004 |
Intraseptal tacrine can enhance memory in cognitively impaired young rats.
Topics: Age Factors; Animals; Cognition Disorders; Dose-Response Relationship, Drug; Female; Injections, Int | 2004 |
Effects of a memory enhancing peptide on cognitive abilities of brain-lesioned mice: additivity with huperzine A and relative potency to tacrine.
Topics: Alkaloids; Animals; Avoidance Learning; Behavior, Animal; Brain Diseases; Cognition Disorders; Disea | 2006 |
Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease.
Topics: Aged; Alkaloids; Alzheimer Disease; Brain; Caregivers; Cholinesterase Inhibitors; Cognition Disorder | 2006 |
Chotosan, a kampo formula, ameliorates chronic cerebral hypoperfusion-induced deficits in object recognition behaviors and central cholinergic systems in mice.
Topics: Acetylcholinesterase; Actins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain Ischemia; Cere | 2007 |
Tacrine approved for cognitive deficits in Alzheimer's disease.
Topics: Alzheimer Disease; Cognition Disorders; Drug Costs; Humans; Tacrine | 1994 |
[Use of cholinesterase inhibitors in Alzheimer disease].
Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Female; Humans; Ma | 1993 |
Tacrine for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Clinical Trials as Topic; Cognition Disorders; Drug Interactions; Humans | 1993 |
[Melatonin, methadone, tacrine, vitamin K antagonists and low-molecular-weight heparin].
Topics: Aged; Anticoagulants; Cholinesterase Inhibitors; Circadian Rhythm; Cognition Disorders; Heroin Depen | 1996 |
Pharmacoeconomics of dementia.
Topics: Alzheimer Disease; Chronic Disease; Clinical Trials, Phase III as Topic; Cognition Disorders; Costs | 1997 |
Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities.
Topics: Aged; Alzheimer Disease; Blood Glucose; Brain; Cognition Disorders; Dose-Response Relationship, Drug | 1998 |
[Drug therapy strategies in Alzheimer's disease].
Topics: Aggression; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Car | 1998 |
Tetrahydroaminoacridine and the central anticholinergic syndrome.
Topics: Aged; Aminoacridines; Anesthesia, General; Cognition Disorders; Confusion; Drug Interactions; Humans | 1987 |